Background: The efficiency of haematopoietic stem and progenitor cells (HSPCs) is important when donor cell numbers are limiting. Stable white blood cell (WBC) and platelet engraftment is crucial for the outcome of haematopoietic stem cell transplantation (HSCT).
introduction CD26/dipeptidylpeptidase-IV is a widely expressed cell surface peptidase that exhibits a complex biology encompassing cell membrane-associated activation of intracellular signal transduction pathways, cell-cell interaction and enzymic activity exhibited by both the membrane-anchored and the soluble forms of the enzyme [1, 2] . CD26 is expressed constitutively on many haematopoietic cell populations, including activated B and T lymphocytes and natural killer cells, endothelial cells, fibroblasts, and epithelial cells [1, 3, 4] , that are involved in migration. The enzyme activity of CD26 is capable of cleaving N-terminal dipeptides from polypeptides with either proline or alanine residues in the penultimate position. CD26-mediated truncation of natural substrates has drastic effects on the biological activity or function. CD26 may also potentially modulate immune responses by directly regulating lymphocytes [5] . On human T cells, CD26 exhibits a costimulatory function. It is known to mediate signalling by direct interaction with cytoplasmic domain of CD45. It was reported that CD26 was involved in interactions with extracellular matrix proteins, collagen and fibronectin.
The role of CD26 expression in haematopoietic stem cell transplantation (HSCT) and modulation of stem cell homing and engraftment has been demonstrated in mouse model using human cord blood haematopoietic stem and progenitor cells (HSPCs) [6] and mouse HSPCs in utero [7] . It was demonstrated that inhibition or deletion of CD26 on donor cells enhanced short-term engraftment, competitive repopulation, secondary transplantation and mouse survival. Animal studies have proven that CD26 is an essential component of normal granulocyte colony-stimulating factor (G-CSF)-induced progenitor cell mobilisation [8, 9] . Contradictory reports have found no effect of CD26 inhibitor on homing of enriched CD34+ cells from mobilised peripheral blood in mice [10] and on multilineage engraftment of green fluorescent protein+ donor bone marrow cells injected in utero in mice [7] .
There is no study reported on CD26 expression on mobilised stem cell product, which is being widely used for transplantation. Therefore, this study was undertaken to analyse CD26 expression on cells in leukapheresis stem cell harvest and evaluate its correlation with engraftment in HSCT.
patients and methods
Human G-CSF-mobilised leukapheresis samples were collected from cancer patients (n = 21) selected for autologous clinical transplantation or from their allogeneic related healthy donors (n = 11). Stem cell harvest or leukapheresis samples were obtained after routine peripheral blood stem cell (PBSC) collection. These samples were obtained after written informed consent of relatives and patients. The procedure for collection of this material was in accordance with procedures approved by the human ethics committee of Tata Memorial Centre. The characteristics, clinical history and treatment record of patients who underwent transplant and who were considered for correlation study (autologous, n = 17; allogeneic, n = 11) are summarised in Table 1 .
Mobilisation was carried out by daily subcutaneous injection of G-CSF. After mobilisation chemotherapy, PBSC counting started when the leukocyte nadir was passed and the absolute leukocyte concentration was >0.5 · 10 9 /l. Cell viability was examined by light microscopy using trypan blue staining (Invitrogen, Grand Island, NY).
CD34 and CD26 expression by flow cytometry
After red cell lysis, nucleated cells from stem cell harvest were suspended in FACS buffer (phosphate-buffered saline with 1% fetal calf serum and 0.02% sodium azide) and stained with anti-human CD26 conjugated to fluorescein isothiocyanate (FITC; BD Pharmingen, San Jose, CA). Cells were stained with isotype mouse IgG1-FITC, which served as control. The presence of human CD34+ cells was identified by staining with anti-CD45-FITC (Becton Dickinson, San Jose, CA) antibodies. The light-scattering properties and the fluorescence of cells stained with FITC were measured on a FACSCalibur flow cytometer (Becton Dickinson, San Jose, USA). For the analysis of antigen levels, the fluorescence signals corresponding to debris and cell aggregates were first gated out using the forward scatter (FSC) and side scatter (SSC) display. Positively stained cells were gated on various gates. Figure 1A depicts the schematic representation of gated population, while Figure 1B shows gated population on a dot plot of representative stem cell harvest. Area with low SSC and FSC properties was marked as 'lymphocyte' (L) gate, that with medium FSC and SSC as 'monocyte' (M) gate, and that with high FSC/SSC as 'neutrophil' (N) gate. Area including all gates was marked as 'all populations' gate. Data were collected, stored and analysed with CELLQuest Software (Becton Dickinson). CD34+ cells were defined as described earlier in the International Society for Hematotherapy and Graft Engineering protocol for CD34 analysis [11] . engraftment studies WBC engraftment was considered to have occurred on the first day of 3 consecutive days in which the absolute count exceeded 1.0 · 10 9 /l. Platelet engraftment was considered to have occurred on the first day of 7 consecutive days in which platelet count exceeded 20 · 10 9 /l. Whole blood was analysed for long-term donor engraftment.
statistical analysis
Results are expressed as mean 6 standard error. Comparison of CD34 or CD26 expression by cells from autologous versus allogeneic stem cell harvest was carried out using the unpaired two-tailed t-test. Correlations for association of CD34/CD26 expression with days of WBC and platelet engraftment were evaluated using Pearson's correlation test. All P values were two tailed and a level of <0.05 was accepted as statistically significant.
results

CD34 and CD26 expression on stem cell harvest
Colocalisation of CD34 and CD45 antigens on HSPCs was observed under laser confocal microscope. Representative picture is shown in Figure 2A . Lower panel shows the distribution of colour intensity of colocalisation. CD34 expression in mobilised PBSC harvest in cancer patients (n = 21) ranged from 0.01% to 3.42%, with mean of 0.58 6 0.16% ( Figure 3A ). As seen in Figure 3A , mobilisation of CD34+ cells in cancer patients was comparable with that seen in allogeneic (n = 11) related healthy donors, with a mean CD34% expression of 0.75 6 0.16%. CD26 cell surface expression was measured on all nucleated cells in stem cell harvests by flow cytometry on gated populations as depicted in Figures 1 and 3B (supplemental Videos S1 and S2, available at Annals of Oncology online). Colocalisation of CD34 and CD26 is shown in Figure  2B . It was observed that CD26 expression on harvest from patients (n = 21) was significantly higher than that observed in allogeneic (n = 11) donors ( Figure 3B ). The mean values of Figure S1 , available at Annals of Oncology online). The faster WBC engraftment seen in autologous cases as compared with allogeneic cases was statistically extremely significant (P < 0.0000001; Supplemental Figure S1 , available at Annals of Oncology online). Engraftment of platelets was achieved with a mean of 11.5 6 0.9 days (range 4-19 days) in autologous cases and 10.9 6 0.9 days (range 7-16 days) in allogeneic transplantation cases (Supplemental Figure S1 , available at Annals of Oncology online). It was observed that the difference between days of platelet engraftment in autologous and allogeneic cases was statistically nonsignificant. All patients showed virtually 100% engraftment of donor lymphoid cells, without any evidence of residual recipient cells.
correlation of CD34 and CD26 expression with engraftment
The correlation study was carried out on patients demonstrating complete remission on transplantation day +30. The CD34 and CD26 expression was correlated with days of WBC and platelet engraftment in 28 patients who underwent autologous (n = 17) and allogeneic (n = 11) transplantation. CD34 expression showed statistically significantly negative correlation with WBC ( In allogeneic transplantation cases, correlation was not statistically significant (supplemental Figure S2 , available at Annals of Oncology online). It was observed that the CD26 expression showed negative Pearson correlation with days of WBC engraftment. As evident in Figure 4B , correlation was extremely statistically significant in autologous + allogeneic cases (L gate: P < 0.00001; M gate: P < 0.00001; N gate: P < 0.00001; all populations: P < 0.00001; Figure 4B panels a-d). Correlation with WBC engraftment was statistically significant in autologous cases (L gate: P = 0.011; M gate: P = 0.017; N gate: P = 0.019; all populations: P = 0.037; Although the association of CD26 expression with platelet engraftment was found to be as negative Pearson correlation, the data were not statistically significant (Supplemental Figure  S3 , available at Annals of Oncology online).
To evaluate the association of CD26 with CD34 expression on cells of stem cell harvest in all transplantation cases, Pearson's correlation test was applied. It was interesting to note that there was no correlation between CD34 and CD26 expression ( Figure 5 panels a-d) .
discussion
CD26 is a transmembrane glycoprotein with intrinsic dipeptidyl peptidase-IV activity that is expressed on numerous cell types and has a multitude of biological functions. An important aspect of CD26 biology is its peptidase activity and its functional and physical association with molecules with key roles in various cellular pathways and biological programs. Role of CD26 in immune regulation has been extensively characterised, with recent findings elucidating its linkage with signalling pathways and structures involved in T-lymphocyte activation as well as antigen-presenting cell-T-cell interaction [12] .
In this study, we have analysed CD26 expression in human mobilised PBSC harvest from cancer patients and allogeneic original article Annals of Oncology related donors. Most of the earlier reported studies on CD26 expression on stem cells were carried out in mice. Earlier studies reported by others showed CD26 expression on CD34+ cord blood cells [13] or Sca-1+ c-kit+ cells in mobilised mice peripheral blood [8] but have studied its correlation with allogeneic HSCT in mice. Bonig et al. [10] have observed low expression of CD26 on enriched CD34+ cells from mobilised peripheral blood than bone marrow samples. Nevertheless, they have not given absolute numbers or percentages of CD26 expression. We observed high expression of CD26 on CD34+ cells (80%-90%; Supplemental Figure S4 , available at Annals of Oncology online). We hypothesised that since complete leukapheresis product is used during transplantation, it is ideal to profile CD26 expression in all cell populations from harvest instead of looking only at CD34+ cells [14] or c-kit+ cells [7] as reported by previous authors.
It is reported that G-CSF up-regulates CD26 expression [14] . In line with this observation, in our study, cells in stem cell harvest post-G-CSF mobilisation of cancer patients showed increased percent expression of CD26 peptidase. Cells in stem cell harvest of allogeneic donors exhibited decreased expression of CD26. The mechanism underlying the decrease in CD26 expression of cells from healthy related donors remains to be investigated. Our study forms the first report that profiles CD26 expression on all cell populations in stem cell harvest. Since soluble CD26 also demonstrates similar activity as membrane-anchored form [1] , investigations of kinetics of soluble CD26 levels in transplanted patients may add valuable information in knowledge towards increasing efficiency of transplantation. Circulating CD26 levels have not been reported earlier in transplantation studies. Nevertheless, in arthritis, decreased circulating CD26 levels have been shown to influence CD26-mediated regulation of stromal derived factor 1 (SDF1)-CXCR4 signaling axis [5] . In our study too, circulating CD26 levels remain to be investigated.
CD26 cleaves a large number of chemokines and peptide hormones in vitro, but comparatively fewer peptides have been identified as endogenous physiological substrates for CD26 in vivo [1] . One of the substrates identified is chemokine SDF1, which plays a crucial role in homing/mobilisation of HSPCs to and from bone marrow to blood and tissues [13, 15] . CD26 plays a crucial role in control of immune function, inflammatory responses and behaviour [1] . Circulatory CD26 has been implicated in modulation of inflammatory response in experimental arthritis [5] . Increased levels of SDF1 and its receptor CXCR4 have been observed in antigen-induced arthritis in CD26 knockout mice. The severity of rheumatoid arthritis has been reported to be negatively associated with CD26 activity and plasma levels [5] . Furthermore, the reduction in natural killer cell antitumour activity [16] and CD4+ T/NKT cell numbers [17] , and reduced plasma levels of cytokines or immunoglobulins and other dysfunction in immune response [18] were observed in CD26 knockout animal models. Bonig et al. [10] observed no effect of CD26 inhibition on homing of mobilised peripheral blood cells. Therefore, CD26 inhibition as reported earlier by others [6] [7] [8] [9] may not be a viable alternative for increasing HSCT efficiency as it may lead to immune imbalance. Instead, our study forms the first report underpinning the inverse correlation of CD26 expression with day of engraftment, i.e. higher expression leads to faster engraftment.
CD34 expression is a known predictor of engraftment. In our study, autologous cases showed good correlation with WBC and platelet engraftment. Nevertheless, in allogeneic cases, CD34 expression failed to exhibit statistical correlation with WBC or platelet engraftment. In both autologous and allogeneic cases, CD34 expression failed to show correlation with WBC but showed significant correlation with platelet engraftment. It was also observed that transplanted CD34+ cell dose did not obtain a close correlation with day of engraftment (data not shown), a phenomenon in agreement with other reports [19] . Other receptors like CD133 in humans [19] or CD49e+ and CD43+ in mice [20] have been implicated as potential markers of engraftment; nevertheless, evidence is needed to prove the results. In this study, we have evaluated CD26 as a potential predictor of engraftment. It was observed that CD26 expression had a strong negative correlation with day of WBC engraftment in autologous transplant, allogeneic transplant and autologous + allogeneic transplant cases. The data corroborated well with day of WBC engraftment and CD26 expression in autologous and allogeneic cases. WBC engraftment for autologous cases was significantly (P = < 0.0000001; Supplemental Figure S1 , available at Annals of Oncology online) faster than that of allogeneic cases. It was observed that CD26 expression level was significantly lower (P <0.001) in allogenic cases as compared with autologous cases ( Figure 3B ). Thus, higher CD26 expression in autologous cases leads to faster WBC engraftment, while lower CD26 expression in allogenic cases leads to slower WBC engraftment. Similar trend of association was also noted in allogeneic cases regarding the association of CD26 expression with platelet engraftment; nevertheless, it was not statistically significant. It was interesting to note that CD34 and CD26 expression exhibited negligible correlation. These data strongly indicate that CD26 may be considered as an independent predictor of engraftment.
In a parallel study, we have observed that SDF1-manipulated HSPC leads to up-regulation of CD26 along with increased ex vivo expansion of progenitor cells (Supplemental Figure S5 , available at Annals of Oncology online). These data support earlier observation by Christopherson et al. [14] that growth factors up-regulate CD26 expression. When nucleated cells from mobilised peripheral blood were incubated in the presence of a mixture of growth factors (with or without SDF1), CD26 expression was significantly up-regulated on these cells.
It was observed that CD26 expression on G-CSF-mobilised peripheral blood cells of healthy donor cases was significantly lower than that on cells from cancer patients. This phenomenon has not been reported anywhere previously and the underlying mechanism needs to be explored.
To summarise, we can say that this study has provided important leads that CD26 peptidase is expressed significantly on cells from mobilised peripheral blood harvest and it shows negative correlation with days of WBC engraftment in transplanted patients. As it failed to show correlation with CD34 expression, which is a known predictor of engraftment, it could be considered as a potential independent predictor of engraftment. We agree that the sample size is very small and a more detailed study with large number of patients and investigation of mechanism underlying the phenomenon is warranted. It would also be important to correlate circulating levels of CD26 with engraftment before we prove association of CD26 expression with engraftment.
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